Skip to main content

Table 1 Association of STAS with clinicopathologic characteristics

From: An individual nomogram can reliably predict tumor spread through air spaces in non-small-cell lung cancer

Data

 

All patients (n = 3075)

STAS

p

Present (n = 617)

Absent (n = 2458)

N (%)

n (%)

n (%)

Patient characteristics

Age

 ≥ 60

1591(51.74)

377(23.70)

1214(76.30)

 < 0.001

 

 < 60

1484(48.26)

240(16.17)

1244(83.83)

 

Sex

Female

1663(54.08)

262(15.75)

1401(84.25)

 < 0.001

 

Male

1412(45.92)

355(25.14)

1057(74.86)

 

Smoking

Never

2486(80.85)

458(18.42)

2028(81.58)

 < 0.001

 

Former/current

589(19.15)

159(26.99)

430(73.01)

 

Tumor site

Left

1191(38.73)

234(19.65)

957(80.35)

0.809

 

Right

1853(60.26)

376(20.29)

1477(79.71)

 
 

Bilateral

31(1.01)

7(22.58)

24(77.42)

 

Surgery form

Thoracotomy

145(4.72)

47(32.41)

98(67.59)

 < 0.001

 

Thoracoscopic surgery

2930(95.28)

570(19.45)

2360(80.55)

 

Surgery types

Sublobectomy

1232(40.07)

101(8.20)

1131(91.80)

 < 0.001

 

Lobectomy or pneumonectomy

1843(59.93)

516(28.00)

1327(72.00)

 

CEA

 < 5

2056(86.31)

260(12.65)

1796(87.35)

 < 0.001

 

 ≥ 5

326(13.69)

131(40.18)

195(59.82)

 

Pathological characteristics

Postoperative pathology

Squamous cell carcinoma

227(7.38)

40(17.62)

187(82.38)

0.604

 

Adenocarcinoma

2783(90.50)

563(20.23)

2220(79.77)

 
 

Large Cell carcinoma

65(2.11)

14(21.54)

51(78.46)

 

Pathological grade

well

534(17.37)

0(0)

534(100)

 < 0.001

 

moderately

1699(55.25)

265(15.60)

1434(84.40)

 
 

poorly

842(27.38)

352(41.81)

490(58.19)

 

ADC type

AIS + MIA + LEP

573(20.59)

0(0)

573(100)

 < 0.001

 

ACI + VIA + PAP

 

1961(70.46)

407(20.75)

1554(79.25)

 

SOL + LCA + MIP

 

249(8.95)

156(62.65)

93(37.35)

SCC type

keratinizing

119(52.42)

19(15.97)

100(84.03)

0.601

 

Nonkeratinizing

108(47.58)

21(19.44)

87(80.56)

 

Lymphatic & blood

−

2799(91.02)

448(16.01)

2351(83.99)

 < 0.001

vessel invasion

 + 

276(8.98)

169(61.23)

107(38.77)

 

Pleural invasion

−

2565(83.41)

398(15.52)

2167(84.48)

 < 0.001

 

 + 

510(16.59)

219(42.94)

291(57.06)

 

T

Tis

56(1.82)

0(0)

56(100)

 < 0.001

 

T1

2227(72.42)

311(13.96)

1916(86.04)

 
 

T2

660(21.46)

243(36.82)

417(63.18)

 
 

T3

60(1.95)

25(41.67)

35(58.33)

 
 

T4

72(2.34)

38(52.78)

34(47.22)

 

N

N0

2677(87.06)

399(14.90)

2278(85.10)

 < 0.001

 

N1

170(5.53)

89(52.35)

81(47.65)

 
 

N2

228(7.41)

129(56.58)

99(43.42)

 

M

M0

3043(98.96)

593(19.49)

2450(80.51)

 < 0.001

 

M1

32(1.04)

24(75.00)

8(25.00)

 

TNM

0

56(1.82)

0(0)

56(100)

 < 0.001

 

IA

2083(67.74)

226(10.85)

1857(89.15)

 
 

IB

406(13.20)

123(30.30)

283(69.70)

 
 

II

233(7.58)

106(45.49)

127(54.51)

 
 

III-IV

297(9.66)

162(54.55)

135(45.45)

 

CK7

−

173(6.06)

21(12.14)

152(87.86)

0.01

 

 + 

2680(93.94)

541(20.19)

2139(79.81)

 

NapsinA

−

403(13.33)

85(21.09)

318(78.91)

0.641

 

 + 

2621(86.67)

526(20.07)

2095(79.93)

 

p63

−

1456(55.66)

322(22.12)

1134(77.88)

0.019

 

 + 

1160(44.34)

213(18.36)

947(81.64)

 

TTF-1

−

290(9.53)

55(18.97)

235(81.03)

0.645

 

 + 

2752(90.47)

557(20.24)

2195(79.76)

 
  1. ADC, adenocarcinoma; SCC, squamous cell carcinoma; AIS, Adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; LEP, lepidic predominant; ACI, acinar predominant; VIA, variants of invasive adenocarcinoma; PAP, papillary predominant; SOL, solid predominant; LCA, lung cribriform adenocarcinoma; MIP, micropapillary predominant; TNM, tumor node metastasis